Circassia Phase II T-cell vaccine study meets safety, efficacy endpoints
In the current trial, the patients received four standardised doses of ToleroMune T-cell vaccine over a number of weeks. During the study, investigators administered a challenge dose of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.